High-performance analytical solutions for residual DNA testing in cell and gene therapy using real-time PCR or digital PCR technologies

Watch the video or view the poster to: Understand what are the regulatory requirements and challenges in residual host cell DNA testing for cell and gene therapies  Benefit from a technology review—real-time PCR versus digital PCR Receive guidance on selecting the best technology for the intended purpose  Gain insights into an integrated workflow solution to support process development and a GMP environment (E.coli and E1A end-to-end workflow)

Christina Bouwens is a dedicated professional in the field of molecular biology and precision medicine research. Currently serving as the Global Market Development Manager for Digital PCR at Thermo Fisher Scientific, Christina brings a wealth of knowledge and experience in digital PCR assay development. She has made significant contributions to the field, particularly in the area of cancer biology. Christina has authored peer-reviewed publications in the field of oncology, including two first authorships, which focus on personalized circulating tumor DNA detection and monitoring using digital PCR technology.

Please enter your email to access content Read now